Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 10 mg, 20 mg, 40 mg) |
| Drug Class | Antidepressants |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indiacted for the treatment of major depressive disorder (MDD) in adults
Latest News
Summary
- This summary is based on the review of five systematic review(s)/meta-analysis(es). [1-5]
- In adults with Major Depressive Disorder (MDD), vilazodone demonstrated a Standardized Mean Difference (SMD) of -0.37 (95% credible interval (CrI): -0.61, -0.12) compared to placebo, indicating superiority but less efficacy than probiotics. It was not highlighted for significant performance in reducing the 6-month relapse rate during the maintenance phase.
- In children and adolescents, vilazodone was associated with a "small and unimportant" reduction in depression symptoms on the Children's Depression Rating Scale–Revised (CDRS-R) scale compared to placebo.
- Compared to other antidepressants, vilazodone showed similar effectiveness to trazodone, agomelatine, and vortioxetine for Ejaculation Dysfunction (EjD) and Erectile Dysfunction (ED) but ranked lower than probiotics in efficacy for treating MDD.
- Vilazodone demonstrated a favorable safety profile for EjD, ED, and decreased libido, with incidences similar to placebo. However, severe toxicity, including serotonin syndrome and seizures, was observed in children after low-dose ingestions, necessitating Intensive Care Unit (ICU) admission and intensive care.
- Long-term treatment tolerability of vilazodone was comparable to probiotics and other antidepressants. No specific safety concerns were noted for vilazodone in the maintenance phase, but single-substance ingestion in adults and adolescents also resulted in serotonin syndrome, frequently requiring intensive care management.
- Vilazodone demonstrated "small and unimportant" effectiveness differences compared to placebo in children and adolescents with MDD, with a high risk of severe toxicity, including serotonin syndrome and seizures, following low-dose ingestion. For adults, vilazodone exhibited satisfactory safety outcomes but lower effectiveness relative to probiotics and was not among the top-performing antidepressants in the maintenance phase.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Viibryd (vilazodone hydrochloride) Prescribing Information. | 2023 | AbbVie Inc., IL, USA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Effect of antidepressants on ejaculation dysfunction in patients with depression and anxiety: A systematic review and network meta-analysis | 2024 | Andrology |
| Probiotics for adults with major depressive disorder compared with antidepressants: a systematic review and network meta-analysis | 2024 | Nutrition Reviews |
| Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis | 2023 | Molecular Psychiatry |
| New generation antidepressants for depression in children and adolescents: a network meta-analysis | 2021 | The Cochrane Database of Systematic Reviews |
| Vilazodone poisoning: a systematic review | 2020 | Clinical Toxicology (philadelphia, Pa.) |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. | 2023 | Annals of Internal Medicine |
| Clinical Guidelines of the Egyptian Psychiatric Association for the Management of Treatment-Resistant Unipolar Depression in Egypt. | 2022 | Frontiers in Psychiatry |
| Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice. | 2022 | Neuropsychiatric Disease and Treatment |
| VA/DoD Clinical practice guideline for the management of major depressive disorder. | 2022 | The Management of Major Depressive Disorder Work Group |